Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | CLPP | Q16740 | 5/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2302925 | 0.92 | CLPP (0.55) | ACHESLC6A5CLPPMEN1GAA | |
| SCHEMBL2301297 | 0.92 | ACHE (0.54) | ACHESLC6A5CLPPAKR1B1GAA | |
| SCHEMBL2300918 | 0.91 | CLPP (0.53) | ACHESLC6A5CLPPAKR1B1PNMT | |
| SCHEMBL2299422 | 0.91 | CLPP (0.53) | ACHESLC6A5CLPPAKR1B1PNMT | |
| SCHEMBL2301137 | 0.86 | SIGMAR1 (0.53) | ACHESLC6A5CLPPAKR1B1MEN1 | |
| SCHEMBL2303506 | 0.86 | CLPP (0.49) | ACHECLPPAKR1B1MEN1KMT2A | |
| SCHEMBL6908503 | 0.85 | ACHE (0.48) | ACHESLC6A5CLPPAKR1B1MEN1 | |
| SCHEMBL2339754 | 0.84 | SIGMAR1 (0.54) | ACHESLC6A5CLPPPNMT | |
| SCHEMBL2304438 | 0.84 | ACHE (0.54) | ACHECLPPKMT2AGABRA1GABRA2 | |
| SCHEMBL6908510 | 0.84 | ACHE (0.46) | ACHESLC6A5CLPPAKR1B1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865758-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-10-21 | — | — | US | claimed |
| EP-2536723-B1 | PYRAZOLO PIPERIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2013-12-11 | — | — | EP | claimed |
| US-20120316163-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | claimed |
| EP-2361911-A1 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GenKyoTex SA (CH) | 2011-08-31 | — | — | EP | claimed |
| US-8865758-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8865758-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8865758-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-10-21 | — | — | US | disclosed |
| EP-2536723-B1 | PYRAZOLO PIPERIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2013-12-11 | — | — | EP | disclosed |
| US-20120316163-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316163-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316163-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | disclosed |
| EP-2361911-A1 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GenKyoTex SA (CH) | 2011-08-31 | — | — | EP | disclosed |
| WO-2011101804-A1 | PYRAZOLO PIPERIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316163-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | NOX1, NOX4, NOX5 | ACHE 1680/4885SLC6A5 4724/4885CLPP 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.